Phase II study of Erlotinib in previously treated advanced non-small cell lung cancer patients with carcinomatous meningitis.

Trial Profile

Phase II study of Erlotinib in previously treated advanced non-small cell lung cancer patients with carcinomatous meningitis.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Dec 2016

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2016 Results analyzing efficacy presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 21 Aug 2015 Status changed from recruiting to active, no longer recruiting as per University Hospital Medical Information Network - Japan record.
    • 05 Jul 2013 Planned end date changed from 1 May 2014 to 31 May 2016 as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top